This funding will support projects that assess the compatibility of several SARS-CoV-2 targets with our ligand and drug screening assay, known as fast quantitative cysteine reactivity (fQCR). If successful, rapid implementation of the fQCR screening assay would be feasible worldwide, as the method is inexpensive and requires equipment common to most basic and clinical research departments (i.e. a thermocycler and fluorometer or SDS-PAGE gel rig). Additionally, we will use fCQR to experimentally validate lead compounds we develop against several SARS-CoV-2 drug targets using our structure-based computational approaches.
laboratory for pharmacological innovation 